685 reports of this reaction
1.9% of all ZIPRASIDONE HYDROCHLORIDE reports
#8 most reported adverse reaction
DYSKINESIA is the #8 most commonly reported adverse reaction for ZIPRASIDONE HYDROCHLORIDE, manufactured by ROERIG. There are 685 FDA adverse event reports linking ZIPRASIDONE HYDROCHLORIDE to DYSKINESIA. This represents approximately 1.9% of all 35,561 adverse event reports for this drug.
Patients taking ZIPRASIDONE HYDROCHLORIDE who experience dyskinesia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSKINESIA is a less commonly reported adverse event for ZIPRASIDONE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to dyskinesia, the following adverse reactions have been reported for ZIPRASIDONE HYDROCHLORIDE:
The following drugs have also been linked to dyskinesia in FDA adverse event reports:
DYSKINESIA has been reported as an adverse event in 685 FDA reports for ZIPRASIDONE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSKINESIA accounts for approximately 1.9% of all adverse event reports for ZIPRASIDONE HYDROCHLORIDE, making it a notable side effect.
If you experience dyskinesia while taking ZIPRASIDONE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.